Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Artirem®' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Artirem®' found in 1 term [] and 2 definitions []
1 - 3 (of 3)     
Result Pages : [1]
MRI Resources 
Safety pool - MRI Physics - Stimulator pool - MRCP - Mobile MRI - Nerve Stimulator
 
Artirem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Artirem®, the arthrography-specific contrast agent for MRI is a dilute form of Dotarem® with a less concentration of Gd (1:200). Artirem® has to be injected directly into the joints for better visualization and delimitation, of the ligament and tendon structures in particular.
Drug Information and Specification
NAME OF COMPOUND
DEVELOPER
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
CONCENTRATION
0,0025 mmol/ml
PREPARATION
Finished product
INDICATION
Arthrography
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Pre-filled syringes of 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
for sale
France, Switzerland
Artirem®
for sale
Australia
for sale
spacer
 
• Share the entry 'Artirem®':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  News & More:
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
MRI Resources 
MRI Reimbursement - MR Guided Interventions - Intraoperative MRI - Education - MRI Accidents - RIS
 
Dotarem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Dotarem® is a paramagnetic ionic MRI contrast agent. Extracellular contrast agents like Dotarem®, can be bolus injected because of the relatively low rate of side effects. This contrast medium is useable to enhance signal intensity in magnetic resonance imaging for intracranial and spinal lesions with an abnormal blood brain barrier or abnormal vascularity, and in whole body imaging.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification
NAME OF COMPOUND
DEVELOPER
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
1350 mosm/kgH2O
CONCENTRATION
0.5 mol/L
DOSAGE
0.1 mmol/kg / 0.2mL/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Vials of 5, 10, 15, 20mL
Pre-filled syringes of 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
for sale
France, Switzerland
Artirem®
for sale
Australia
for sale
spacer

• View the DATABASE results for 'Dotarem®' (7).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
  News & More:
RSNA Statement on Gadolinium-Based MR Contrast Agents
Thursday, 1 February 2018   by www.rsna.org    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
MRI Resources 
NMR - Societies - Open Directory Project - Movies - Knee MRI - Fluorescence
 
Guerbet S.A.
 
www.guerbet.com/home_va.html The France-based Guerbet Group is highly specialized in contrast media for medical imaging. Its strategic goal is to be a key player in this market. Products include Dotarem (Magnetic Resonance Imaging) and Xenetix (X-ray Imaging).

MRI Contrast Agents:
Contact Information
MAIL
Guerbet
Boite postale 50400
95943 Roissy
Charles de Gaulle Cedex
FRANCE
PHONE
+33-1-45-91-50-00
FAX
+33-1-45-91-51-99
spacer

• View the DATABASE results for 'Guerbet S.A.' (7).Open this link in a new window


• View the NEWS results for 'Guerbet S.A.' (2).Open this link in a new window.
 
Further Reading:
  Basics:
Guerbet Completes Acquisition of Mallinckrodt’s Contrast Media and Delivery Systems Business
Sunday, 29 November 2015   by www.itnonline.com    
  News & More:
Guerbet to Spotlight Diagnostic and Interventional Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting
Tuesday, 3 January 2023   by www.itnonline.com    
Guerbet to Spotlight the Novel New Drug Elucirem (gadopiclenol) injection at RSNA22
Saturday, 26 November 2022   by www.itnonline.com    
Guerbet receives EMA acceptance of Elucirem™ as the Brand Name for Gadopiclenol
Monday, 13 June 2022   by www.prnewswire.com    
Gadopiclenol: positive results for Phase III clinical trials
Monday, 29 March 2021   by www.pharmiweb.co    
MRI Resources 
Portals - Supplies - Software - Devices - Cardiovascular Imaging - Developers
 
     1 - 3 (of 3)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



How AI will impact MRI :
only diagnostics 
saving time 
reducing cost 
makes planning obsolete 
reduce human knowledge 
not at all 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 18 December 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]